AstraZeneca or Daiichi Sankyo Enhertu gets EU approval for HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
By, Admin1 min read
Share
AstraZeneca and Daiichi Sankyo
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.